*Packaging may vary based on availability.
Generic for Diprosone · High-potency cream/ointment · 45g
Betamethasone dipropionate 0.05% is a high-potency fluorinated corticosteroid — one step below the super-high-potency class, and substantially stronger than mid-range agents like triamcinolone or mometasone. It’s not a first-line option for eczema. It’s the drug your clinician reaches for when the situation calls for faster, more complete clearance than a mid-potency compound can deliver: severely inflamed, thickened patches that have been present for weeks, extensive trunk involvement, or flares on the palms and soles where skin is thick and inflammation is more refractory.
Used correctly — short courses, on appropriate body areas, not on the face or folds, not chronically — betamethasone dipropionate has a well-established clinical role. The risks are real, but they’re well-characterized and largely avoidable with proper prescribing and patient education.
Same mechanism as other topical corticosteroids — glucocorticoid receptor binding, NF-κB suppression, reduced cytokine production — but at significantly higher potency. The dipropionate ester and the fluorine atom at the 9-alpha position both increase receptor affinity and enhance penetration through the skin barrier. In practical terms it suppresses the same inflammatory mediators as lower-potency steroids, just more rapidly, more completely, and at greater depth in the dermis.
The ointment formulation is the more potent vehicle. The cream stocked here is the non-augmented version, which sits in Class III (high potency) rather than the super-high-potency augmented gel/ointment. Vasoconstriction and cytokine shutdown are visible within days.
High-potency topical steroids as a class have strong RCT evidence for moderate-to-severe atopic dermatitis and plaque psoriasis. Betamethasone dipropionate specifically has decades of controlled trial data and numerous head-to-head comparisons against mid-potency agents, with consistent findings: faster clearance and higher complete-response rates for established flares on body sites, compared to Class IV and V agents. It appears in treatment algorithms as the step-up when adequate response isn’t achieved on mid-potency.
For eczema, the evidence supports short-course use (typically 1–2 weeks) for acute exacerbations, not ongoing management. The risk-benefit calculation shifts unfavorably with longer use.
Not for the face, neck, eyelids, groin, underarms, or any skin fold. These are not soft guidelines. Using a high-potency steroid on facial or flexural skin can cause irreversible atrophy and telangiectasia (visible surface vessels) within weeks. Not for children. The pediatric HPA-axis suppression risk on this potency class is unacceptable for routine eczema management — Fern doesn’t prescribe betamethasone to patients under 18.
Not for continuous or long-term use. Two weeks maximum on any area is the standard upper limit; atrophy can appear within 2–3 weeks of daily use even on appropriate skin, and HPA-axis suppression scales with surface area, duration, and occlusion. Not for thin skin or infected skin. The immunosuppressive effect at this potency can let a bacterial or viral infection spread rapidly. If the flare hasn’t cleared in two weeks, that’s a signal to step down, not to extend the course.
| Traditional | With Fern | |
|---|---|---|
| Doctor appointment | ~30 days to book | 5-hour clinician review |
| Getting the Rx | Separate pharmacy trip | Shipped to your door |
| Cost | Insurance + copays | $35/mo, no insurance |
| Follow-up | Second appointment | Message the care team |
Betamethasone dipropionate is the appropriate step-up when mid-potency steroids (triamcinolone, fluticasone, mometasone) haven’t produced adequate clearance after a full course, or when the initial presentation is severe enough — thick, lichenified patches on the trunk or limbs — that starting with a mid-potency agent is unlikely to be sufficient. Your clinician won’t prescribe it for mild-to-moderate eczema, or for eczema on the face or folds.
Typically no more than 2 consecutive weeks on any area. After the flare clears, stop. Do not use it continuously or as maintenance — both atrophy and HPA-axis suppression risk rise substantially with duration. If you need ongoing management, that’s a conversation about stepping down to a mid-potency maintenance strategy or considering non-steroidal options.
Trunk, arms, legs, back, palms, and soles. The palms and soles are among the most appropriate sites for high-potency steroids because the skin is significantly thicker there — dyshidrotic eczema (blistering eczema of the hands) and palmoplantar eczema can be resistant to mid-potency steroids and often benefit from short betamethasone courses. Not the face, neck, eyelids, groin, underarms, or skin folds.
Wash it off with water immediately. One inadvertent application is unlikely to cause lasting harm, but don’t continue using it there. If you’ve been applying it to your face for several days, examine the skin for increased shininess, visible surface vessels, or unusual fragility, and contact your clinician.
After a short course (1–2 weeks) on appropriate areas, stopping without taper is generally fine. After longer use, some patients experience a rebound flare, and there’s a condition called topical steroid withdrawal (sometimes called red skin syndrome) associated with prolonged widespread use of high-potency steroids. This is more of a risk with months of inappropriate use than with a properly supervised short course. If you’ve been using betamethasone for an extended period, discuss the discontinuation approach with your clinician.
Fern clinicians review every case individually. Most patients hear back in under 3 hours.
Start your assessment →This information is for educational purposes only and is not medical advice. Consult with a healthcare provider before starting any treatment.
“There’s a specific look I recognize in eczema patients who’ve been managing on their own too long. They’ve stopped believing it can get better. Fern shortens that window of suffering. It gets people into real treatment before hopelessness sets in.”